Syntaxin Ltd was established in 2005. The Company closed a £6M Series A financing in November 2005, led by Abingworth Management.
Prior to the formation of Syntaxin, the biotech research programmes were carried out at the Health Protection Agency (HPA) with grant support from the UK Department of Health and UK research councils, and sponsorship from Ipsen Ltd (formerly The Speywood Laboratory and Porton International Ltd).
The Company benefits from a strategic alliance with Allergan Inc, signed in 2000, for the discovery, development and commercialisation of proprietary engineered neurotoxin drugs for the treatment on pain disorders. The biopharmaceutical company receives substantial revenues through this alliance and values close collaboration with Allergan, the global leader in the biopharmaceutical and cosmetic market for botulinum toxin medicines (botox).